Dr. Abha Kumari

   MBBS , DNB Radiotherapy

Book An Appointment

Home / Doctors / Dr. Abha Kumari

Dr. Abha Kumari


MBBS , DNB Radiotherapy


Radiation Oncology


HCG EKO Cancer Centre - Kolkata


7+ Years

  • Experienced in administering high end radiotherapy techniques like 3DCRT, IMRT, VMAT, respiratory gating therapy, IGRT, SRS, SRT, brachytherapy etc
  • Extensive experience in research in the field of head and neck cancer and breast cancer
  • Worked with renowned healthcare institutions like Amrita Institute Medical Science, Kerala, Tata Medical Centre, Kolkata, International Oncology Group, Fortis, Noida and Mahavir Cancer Sansthan, Patna.
  • Rita R, Singh U, Trivedi V, Chauhan R, Kumari A (2017) Determinants of Survival of Cervical Cancer: A Hospital Based Study. Gynecol Obstet 7: 437. doi:10.4172/2161-0932.1000437.
  • Chatterjee S, Chakraborty S; HYPORT Adjuvant Author Group. Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)-study protocol for a multicentre, randomized phase III trial. Trials. 2020;21(1):819. Published 2020 Sep 30. doi:10.1186/s13063-020-04751-y
  • S. Bhusal, S. Chatterjee, S. Chakraborty, A. Kumari, S. Bachianathan, A. Mahato, P. Lal, S. Gupta, P. Solomon, K.M. Das, S. Mandal. PO-1797: Dosimetric analysis of simultaneous integrated boost in the HYPORT Adjuvant Trial (NCT03788213). DOI:10.1016/S0167-8140(21)01815-6. ESTRO 2020 abstract
  • Ritesh santosham, Sanjoy Chatterjee, Santam Chakraborty, Avipsa Das, Abha Kumari Hypofractionated Radiotherapy with SIB in Advanced Incurable Breast Cancer -HYPORT B study (NCT03669497). DOI:10.13140/RG.2.2.36479.64160, ESTRO 2020 abstract
Area of Interest
  • Head and Neck cancer
  • Breast cancer
  • Gynecological cancer
Clinical Research
  • Co-investigator in National cancer registry program (NCRP) in Mahavir Cancer Sansthan, Patna
  • Principal investigator in Quality of life and employment status in head and neck cancer patients from rural area, treated at a tertiary cancer center in tier II city of India: A Prospective cross-sectional study
  • Co-investigator in a Intensifying radiation treatment in advanced/ poor prognosis laryngeal, hypopharyngeal (LH) and oropharyngeal cancers (OPC) using PET –CT based dose escalation strategies. (INTELHOPE)
  • Co-investigator in HYPOfractionated Radiation Therapy comparing a standard radiotherapy schedule (over three weeks) with a novel one-week schedule in Adjuvant breast cancer: An open label randomized controlled study (HYPORT- Adjuvant)
  • Co-Investigator in Hypofractionated Radiotherapy schedule of 26 Gy in 5 fractions with simultaneous integrated boost (6 Gy) in advanced incurable breast cancer: A prospective Phase I/II study.
  • Co-Investigator in a prospective, multicenter, randomized, double blind, parallel group study to compare the efficacy and safety of biosimilar cetuximab versus innovator cetuximab in combination with platinum-based chemotherapy in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (ALK18/ENZ124-CET1)
  • Co-investigator in a phase III, double-blind, placebo-controlled, randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumors (ADD-Aspirin, breast cancer cohort)
  • Co-investigator in a Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti−PD-L1 Antibody) in Combination with Paclitaxel Compared with Placebo with Paclitaxel for Patients with Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer (MO39196)
  • Co-investigator in a Phase II, multicenter, open-label, two-cohort, non-comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2 – negative advanced breast cancer ( aBC ), who have progressed on or after CDK 4/6 inhibitor treatment (CBYL719X2402)
  • Co-investigator in a randomized, Double-Blind, Multi-Centre, Parallel Group Study Comparing Two Humanized Monoclonal Antibodies that Target HER2 Receptors in Combination with Weekly Paclitaxel Administered as First-Line Treatment in Patients with HER2-Positive Metastatic Breast Cancer (TZ-01-002)
  • Co-investigator in a Phase III, Double Blind, Placebo-Controlled, Randomized study of Ipatasertib in combination with Atezolizumab and Paclitaxel As a treatment for patients with Locally Advanced Unresectable or Metastatic Triple – Negative Breast Cancer (CO41101)
  • Co-investigator in a Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Her2-Positive Breast Cancer at High Risk Of Recurrence Following Preoperative Therapy (WO42633).

   Practices at

Other Doctors